Physician profile
Christopher Johnson
NPI 1801415195
$2,898.62
in general payments reported to CMS, 2019-2025
20 companies · $1,534 in 2025
The $1,534 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $174 · 2024: $1,190 · 2025: $1,534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,898.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $547.76 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $523.20 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $328.95 | 2023-2025 | |
| Lilly USA, LLC | $257.37 | 2024-2025 | Mounjaro, Zepbound, Kisunla |
| Exact Sciences Corporation | $185.36 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Stryker Corporation | $134.55 | 2025 | Clottriever Bold Catheter |
| Amgen INC. | $133.36 | 2024-2025 | Otezla, Repatha, Otezla |
| Dermavant Sciences, INC. | $129.11 | 2024 | Vtama |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.08 | 2024-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $111.77 | 2024-2025 | |
| Glaxosmithkline, LLC. | $111.54 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $81.02 | 2024-2025 | Veozah |
| Inspire Medical Systems, INC. | $55.43 | 2025 | Inspire |
| Phathom Pharmaceuticals, INC. | $45.59 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.30 | 2025 | Jardiance |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $26.10 | 2024 | Sunosi |
| Sanofi Pasteur INC. | $22.15 | 2025 | |
| Merck Sharp & Dohme LLC | $22.01 | 2025 | Gardasil 9, M-M-R II, Capvaxive |
| Sumitomo Pharma America, INC. | $20.72 | 2025 | Gemtesa |
| Abbvie INC. | $14.25 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.